IM erythropoietin vs oral placebo
Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 3.5 [1.44, 8.48]1 study · 34 participantsVery low